論文・出版
ALTTO試験
黒井克昌
Cancer Board 乳癌. 2008; 1(1): 58.
Neoadjuvant endocrine therapy with exemestane followed by response-guided combination therapy with low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer: a multicenter, open-label, phase II study Short title: Tailored neoadjuvant therapy for breast cancer
Nobuaki Sato, Norikazu Masuda, Takashi Morimoto, Takayuki Ueno, Chizuko Kanbayashi, Koji Kaneko, Hiroyuki Yasojima, Shigehira Saji, Hironobu Sasano, Satoshi Morita, Shinji Ohno, Masakazu Toi
Cancer Medicine. 2018 Jun; 7(7): 3044-3056. Online ahead of print.
https://doi.org/10.1002/cam4.1600
A multicenter phase II trial of neoadjuvant letrozole plus low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer (JBCRG-07): therapeutic efficacy and clinical implications of circulating endothelial cells
Takayuki Ueno, Norikazu Masuda, Shunji Kamigaki, Takashi Morimoto, Futoshi Akiyama, Masafumi Kurosumi, Hitoshi Tsuda, Yoshiki Mikami, Sunao Tanaka, Satoshi Morita & Masakazu Toi
Cancer Medicine. 2018 Jun; 7(6): 2442-2451. Epub 2018 May 7.
https://doi.org/10.1002/cam4.1516
Factors associated with prolonged time to treatment failure with fulvestrant 500 mg in patients with post-menopausal estrogen receptor-positive advanced breast cancer: a sub-group analysis of the JBCRG-C06 Safari study.
Hidetoshi Kawaguchi, Norikazu Masuda, Takahiro Nakayama, Kenjiro Aogi, Keisei Anan, Yoshinori Ito, Shoichiro Ohtani, Nobuaki Sato, Shigehira Saji, Toshimi Takano, Eriko Tokunaga, Seigo Nakamura, Yoshie Hasegawa, Masaya Hattori, Tomomi Fujisawa, Satoshi Morita, Miki Yamaguchi, Hiroko Yamashita, Toshinari Yamashita, Yutaka Yamamoto, Daisuke Yotsumoto, Masakazu Toi, Shinji Ohno
Current Medical Research and Opinion. 2018 Jan; 34(1): 49-54.
https://doi.org/10.1080/03007995.2017.1400426
医師主導治験の実施体制整備状況と課題について：乳癌診療施設に対するアンケート調査（JBCRG-Q06）
JBCRG-Q06 坂東裕子、笠井宏委、青儀健二郎、大谷彰一郎、津川浩一郎、森岡由香、山口ひとみ、吉波哲大、橋本郁子、相馬道郎、戸井雅和、増田慎三、大野真司
乳癌の臨床. 2017 Nov; 32(6): 477-483.
A phase I/II pharmacokinetics/pharmacodynamics study of irinotecan combined with S-1 for recurrent/metastatic breast cancer in patients with selected UGT1A1 genotypes (the JBCRG-M01 study)
Hiroshi Ishiguro, Shigehira Saji, Shogo Nomura, Sunao Tanaka, Takayuki Ueno, Masahide Onoue, Hiroji Iwata, Takeharu Yamanaka, Yasutsuna Sasaki, Masakazu Toi
Cancer Medicine. 2017 Dec; 6(12): 2909-2917.
https://doi.org/10.1002/cam4.1258
アンケート調査からみる医師主導治験の課題と展望
笠井宏委、坂東裕子、青儀健二郎、大野真司
Cancer Board of the Breast. 2017 Aug; 3(2): 52-53(116-117).
Effectiveness of Fulvestrant in Advanced or Metastatic Breast Cancer Patients in the Real World: A Retrospective Multi-center Cohort Study with 1072 Patients (JBCRG-C06; Safari)
Hidetoshi Kawaguchi, Norikazu Masuda, Takahiro Nakayama, Kenjiro Aogi, Keisei Anan, Yoshinori Ito, Shoichiro Ohtani, Nobuaki Sato, Shigehira Saji, Eriko Tokunaga, Seigo Nakamura, Yoshie Hasegawa, Masaya Hattori, Tomomi Fujisawa, Satoshi Morita, Miki Yamaguchi, Yutaka Yamamoto, Shinji Ohno and Masakazu Toi
Breast Cancer Research and Treatment. 2017 Jun; 163(3): 545-554. Epub 2017 Mar 23.
https://doi.org/10.1007/s10549-017-4212-x
JBCRGのあらたな取り組み -JCBRGの設立と経緯および臨床試験への取り組み
大野真司
医学のあゆみ. 2017 May; 261(5): 572-576.
Outcomes of trastuzumab therapy in HER2‑positive early breast cancer patients (JBCRG-C01)
Hiroyasu Yamshiro · Hiroji Iwata · Norikazu Masuda · Naohito Yamamoto · Reiki Nishimura · Shoichiro Ohtani · Nobuaki Sato · Masato Takahashi · Takako Kamio · Kosuke Yamazaki · Tsuyoshi Saito · Makoto Kato · Tecchuu Lee · Shinji Ohno · Katsumasa Kuroi · Toshimi Takano · Masahiro Takada · Shinji Yasuno · Satoshi Morita · Masakazu Toi
International Journal of Clinical Oncology. 2015 Aug; 20(4): 709-722.
https://doi.org/10.1007/s10147-015-0785-8